Cerus Corporation Submits CE Mark Application For European Approval Of The Intercept Blood System For Plasma

CONCORD, Calif.--(BUSINESS WIRE)--Dec. 30, 2005--Cerus Corporation (NASDAQ:CERS) announced today the submission of a CE Mark application for approval to market the INTERCEPT Blood System for plasma in Europe. The system, which is being jointly developed by Cerus and Baxter Healthcare Corporation, is designed to reduce the risk of transfusion-transmitted diseases. It inactivates pathogens such as HIV, hepatitis B and C viruses, bacteria, and parasites that may be present in donated plasma intended for transfusion.

MORE ON THIS TOPIC